logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Dyslipidemias

    FiltersReset Filters
    10 results

    • fenofibrate

      (fenofibrate)
      Mylan Pharmaceuticals Inc.
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for adults with primary hypercholesterolemia or mixed dyslipidemia, aiming to improve cholesterol levels. They are also used for treating severe hypertriglyceridemia, although their effect on reducing coronary heart disease risks in type 2 diabetes patients remains unproven.

    • fenofibrate

      (fenofibrate)
      Solco Healthcare US, LLC
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for adults with primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia. They help reduce LDL-C, total cholesterol, triglycerides, and Apo B, while increasing HDL-C. They do not reduce coronary heart disease morbidity or mortality in diabetes patients.

    • fenofibrate

      (Fenofibrate)
      Macleods Pharmaceuticals Limited
      Usage: Fenofibrate is indicated as adjunctive therapy to diet for reducing low-density lipoprotein cholesterol, triglycerides, and apolipoprotein B while increasing high-density lipoprotein cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia and for treating severe hypertriglyceridemia.

    • fenofibrate

      (Fenofibrate)
      Alembic Pharmaceuticals Inc.
      Usage: Fenofibrate is indicated as adjunctive therapy to diet for reducing LDL cholesterol, total cholesterol, triglycerides, and Apo B in adults with primary hypercholesterolemia and mixed dyslipidemia, as well as for managing hypertriglyceridemia in specific Fredrickson types. It is not suitable for type I hyperlipoproteinemia.

    • fenofibrate

      (Fenofibrate)
      AustarPharma, LLC
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for adults with primary hypercholesterolemia or mixed dyslipidemia, reducing LDL-C and triglycerides while increasing HDL-C. They are also indicated for severe hypertriglyceridemia. However, fenofibrate does not reduce coronary heart disease morbidity in type 2 diabetes patients.

    • fenofibrate

      (Fenofibrate)
      Alembic Pharmaceuticals Inc.
      Usage: Fenofibrate tablets are indicated as adjunctive therapy to diet for reducing LDL-C, total cholesterol, triglycerides, and apolipoprotein B, while increasing HDL-C in adults with primary hypercholesterolemia or mixed dyslipidemia, and for treating severe hypertriglyceridemia. Limitations include lack of efficacy in reducing coronary heart disease risks in diabetic patients.

    • fenofibric acid

      (Fenofibric acid)
      Micro Labs Limited
      Usage: Fenofibric acid delayed-release capsules are indicated as adjunctive therapy to diet for reducing triglycerides in severe hypertriglyceridemia and for lowering LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, while increasing HDL cholesterol in patients with primary hypercholesterolemia or mixed dyslipidemia.

    • lovastatin

      (lovastatin)
      Lupin Pharmaceuticals, Inc.
      Usage: Lovastatin is indicated for lowering total and LDL cholesterol levels as part of a treatment strategy in individuals with dyslipidemia at risk for atherosclerotic vascular disease, including those with coronary heart disease and hypercholesterolemia. It is also used for primary prevention of coronary heart disease in certain populations.

    • niacin

      (Niacin)
      Chartwell RX, LLC
      Usage: Niacin extended-release tablets are indicated as an adjunct to diet for reducing elevated cholesterol and triglycerides, increasing HDL, and decreasing the risk of recurrent myocardial infarction in hyperlipidemic patients. It also helps slow atherosclerotic disease progression in those with a history of coronary artery disease.

    • rosuvastatin calcium

      (ROSUVASTATIN CALCIUM)
      PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS
      Usage: Rosuvastatin is indicated to treat hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, and homozygous familial hypercholesterolemia. It aids in slowing atherosclerosis progression and primary prevention of cardiovascular disease in at-risk adults. It should be used alongside dietary management.